A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple-Dose Subcutaneous Administration of MEDI-563, a Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma.

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple-Dose Subcutaneous Administration of MEDI-563, a Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 08 Jan 2016 Pooled analysis of 2 trials including 24 patients from this study and another study (see CTP700033389) were published in the Respiratory Medicine.
    • 25 Aug 2014 Planned number of patients changed from 24 to 25.
    • 04 May 2012 Actual patient number is 25 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top